In diabetic IRI model, Dapagliflozin can effectively improve FAO dysfunction and inhibit abnormal glycolysis by activating SIRT3/PGC-1α signaling pathway, thus providing renal protection (Li H. et al., 2024). The gene discussed is PPARGC1A; the disease is diabetes mellitus.